This bill amends the Federal Food, Drug, and Cosmetic Act to increase federal oversight of drug compounding and outsourcing. It adds new definitions and administrative obligations intended to curb routine reproduction of commercially available medicines by compounders, expands FDA inspection triggers for high‑volume outsourcing facilities, requires certain annual reporting, and shifts the statute’s fixed base fee to an amount set by the Secretary.
For compliance officers and legal teams, the bill converts several largely qualitative limits into countable, reportable triggers and creates new inspection and registration consequences for high‑volume compounders. That changes how pharmacies, physician compounders, and outsourcing facilities should assess volume, interstate distribution, and recordkeeping practices today.
At a Glance
What It Does
The bill (1) constrains routine compounding of products that are effectively copies of commercially available drugs using a numeric cap; (2) requires annual reporting to FDA when compounders dispense such products across state lines above a threshold; (3) treats outsourcing facilities that compound at higher volumes as subject to pre‑use and biennial inspections and removes a registration exemption; and (4) replaces a statutory fixed base establishment fee with an amount the Secretary sets to fund oversight.
Who It Affects
Traditional compounding pharmacies, physician compounders who ship out‑of‑state, and outsourcing facilities that produce sizable volumes will face new counting, reporting, and inspection obligations; hospital on‑premises pharmacies are excluded from the new reporting rule. FDA will take on new inspection and data‑analysis tasks; manufacturers of approved drugs may see reduced competition from routine copies.
Why It Matters
The bill converts judgments about when compounding becomes a de facto substitute for a commercial product into objective triggers and mandatory reporting, making enforcement more predictable but also creating hard cutoffs that could affect patient access and business models. For firms, volume accounting and interstate shipment practices now determine regulatory status.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill revises the FDCA’s compounding framework by adding bright‑line elements and administrative duties. It modifies the statutory definition and limits on compounding so that products that merely replicate a commercially available drug are subject to a usage cap; the statute now ties the concept of an unlawful or restricted “copy” to whether the compounded product contains an active ingredient found in a marketed product and whether the prescribing clinician documents a patient‑specific change that produces a meaningful difference for that patient.
It also creates an annual reporting duty for any pharmacy, outsourcing facility, or physician that, within a month, compounds more than the numeric threshold of those “copy” products for patients who live outside the State where the compounding occurs. Reports must identify each type of product and how many times it was compounded in each month and are to be submitted in the form and manner the Secretary prescribes; the text specifies calendar year 2025 as the first year the rule applies and requires submission by year‑end for any applicable year.
The bill excludes hospital inpatient pharmacies located on hospital premises from this reporting duty.For outsourcing facilities, the bill tightens inspection practices and registration consequences. Facilities that cross a higher annual volume threshold are subject to an initial inspection before they compound for the first time and must be reinspected at least once every two years thereafter.
The measure removes an exemption that previously insulated certain entities from registration and reporting under section 510(g)(1), which effectively brings high‑volume outsourcing facilities into FDA’s registration universe. Those inspection and registration changes come into force six months after enactment, giving firms and FDA a short implementation window.Finally, the bill replaces a fixed $15,000 statutory base establishment fee with a directive that the Secretary set a base fee “deemed appropriate” to fund activities related to compounded drug safety.
That change hands the fee level to agency rulemaking or guidance rather than a fixed statutory figure, allowing fee revenue to track future oversight needs but also creating administrative discretion over cost allocation.
The Five Things You Need to Know
The bill bars compounding of a drug product that is 'essentially a copy' of a commercially available drug more than 20 times in a single month.
It defines 'essentially a copy' to require both (A) the same active ingredient as a marketed product and (B) absence of a prescriber‑documented, patient‑specific change that produces a significant difference for that patient.
Pharmacies, outsourcing facilities, or physicians that compound such products for out‑of‑state patients more than the monthly threshold must file an annual report identifying each product type and monthly counts for that calendar year, submitted by year‑end.
Outsourcing facilities that compound more than 100 times in a calendar year are designated 'large‑scale' and face an FDA inspection before first compounding and at least biennial reinspections; the bill also removes a registration exemption for outsourcing facilities.
The statute’s $15,000 base establishment fee is replaced with a discretionary base amount set by the Secretary to fund compounded drug safety activities.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s formal name (SAFE Drugs Act of 2025). This is purely titular but useful when mapping the bill into internal compliance trackers and for referencing the measure in guidance and rulemaking preambles.
Tightened definition and numeric cap on 'copy' compounds
Rewrites the statutory language governing when a compounded product is treated as essentially duplicative of a marketed drug and inserts a numeric ceiling (20 times in a single month) on compounding such products. Practically, firms must now evaluate each compounded SKU against the two‑part test: whether the active ingredient matches a marketed product and whether the prescriber has recorded a patient‑specific modification that meaningfully changes the product for that patient. That shifts part of the substantive judgment onto prescribers’ determinations and creates a count‑based compliance metric for compounders.
Annual reporting for interstate compounding
Adds a new subsection requiring annual reports to FDA when a compounder exceeds the monthly threshold for products containing an active ingredient present in a marketed drug for patients who reside outside the State of compounding. The reports must list each product type and the monthly frequency of compounding, and they are due by the end of the calendar year in which the activity occurred (first applicable year: 2025). The provision includes a hospital pharmacy exclusion for on‑premises hospital compounding, limiting the rule’s reach for inpatient hospital operations.
Pre‑use and biennial inspections for large outsourcing facilities; registration change
Creates a new subcategory of 'large‑scale outsourcing facility' for entities that compound more than 100 times in a calendar year and requires an FDA inspection before the facility compounds for the first time as well as reinspections at least every two years. The bill also clarifies that an exemption under section 510(g)(1) does not apply to outsourcing facilities, which has the practical effect of bringing those entities into FDA registration/notification and related reporting requirements. Both the inspection and registration changes take effect six months after enactment, imposing a short window for operational adjustments.
Secretary discretion over base establishment fee
Removes a statutory fixed $15,000 base establishment fee and replaces it with a standard that the Secretary set a base amount 'deemed appropriate' to fund activities ensuring the safety of compounded drug products. That amendment ties funding for FDA oversight of compounding to an administrable figure rather than a legislatively fixed number, allowing fee levels to be updated without additional congressional action but increasing administrative discretion.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients receiving FDA oversight: Increased inspection frequency for high‑volume outsourcing and mandatory reporting gives FDA more data and inspection authority, which can reduce risks from improperly compounded products.
- FDA and federal regulators: The bill supplies structured reports and objective volume thresholds that make it easier for the agency to prioritize inspections, identify repeat behavior, and build enforcement cases.
- Manufacturers of commercially available drugs: By restricting routine compounding of products that effectively reproduce marketed drugs, the measure reduces substitution risk from compounders when approved products are on the market.
- Hospital in‑house pharmacies: The statutory reporting exclusion for on‑premises hospital compounding preserves hospital inpatient workflows and avoids new reporting obligations for those operations.
Who Bears the Cost
- Independent compounding pharmacies and physician compounders: They must implement new counting methods, track patient residency for interstate shipments, prepare annual reports, and possibly limit production of certain products, which raises compliance and lost‑revenue risks.
- Outsourcing facilities exceeding the 100‑per‑year threshold: These entities face pre‑use inspections, at least biennial reinspections, and the loss of a registration exemption, which increases administrative and operational costs and may require staffing or facility upgrades.
- Prescribing practitioners: The statute ties legality of some compounding to a prescriber’s determination of a 'significant difference,' which increases documentation burdens and potential medico‑legal exposure if a prescriber’s assessment is later questioned.
- FDA resource planners: The agency must staff pre‑use and biennial inspections and process a new stream of annual reports, requiring budgetary and operational adjustments—especially if the Secretary increases fees to cover oversight but timing and sufficiency are uncertain.
Key Issues
The Core Tension
The central dilemma is balancing stronger, data‑driven oversight to protect patients from routine, unregulated copies of commercial drugs against the risk that blunt numeric limits and reporting protocols will restrict legitimate individualized compounding, impose heavy compliance burdens on small practitioners, and push activity into regulatory gaps or hospital settings where access and cost dynamics differ.
The bill replaces qualitative enforcement with numeric triggers. That makes agency decisions more predictable but invites strategic behavior: firms can reorganize production across entities or states to remain below thresholds, or route patients through hospital pharmacies to avoid reporting.
The statute’s reliance on a prescriber’s determination of a 'significant difference' delegates a key legal question to clinical judgment without defining that term, creating uneven application across prescribers and potential litigation over what documentation suffices.
Operationally, the new annual reporting requirement depends on accurate determination of patient residency and on the Secretary issuing forms and submission standards; those details will materially affect compliance cost. The inspection expansion for large‑scale outsourcing facilities assumes FDA will have the inspection capacity and budget to meet pre‑use and biennial demands; without extra resources, the statutory schedule could produce inspection backlogs or uneven enforcement.
Finally, replacing a fixed statutory fee with a Secretary‑set amount gives the agency flexibility but reduces predictability for registrants and could lead to litigation or political pushback if fees are viewed as arbitrary or disproportionate.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.